Literature DB >> 30590814

ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1.

Tongle Zhi1,2, Kuan Jiang3, Xiupeng Xu1, Tianfu Yu1, Fengqi Zhou1, Yingyi Wang1, Ning Liu1, Junxia Zhang1.   

Abstract

BACKGROUND: Epithelial cell transformation sequence 2 (ECT2) is upregulated in glioma and promotes glioma cell proliferation. A preliminary experiment showed a positive correlation between ECT2 and pituitary tumor-transforming gene 1 (PTTG1). The aim of this study was to explore how ECT2 affects PTTG1 to influence the proliferation of glioma cells.
METHODS: The expression of ECT2 in glioma was detected by western blot and reverse transcription PCR. The effect of ECT2 on glioma proliferation was examined using cell proliferation-related assays and in vivo experiments. The effect of ECT2 on the stability of E2F transcription factor 1 (E2F1) and the expression of PTTG1 were examined by western blot, co-immunoprecipitation, and in vivo ubiquitination assays.
RESULTS: ECT2 was upregulated in gliomas and was negatively correlated with prognosis; its downregulation inhibited glioma cell proliferation. Furthermore, ECT2 regulated PTTG1 expression by affecting the stability of E2F1, thereby affecting the glioma cell proliferation. In addition, the deubiquitinating enzyme proteasome 26S subunit, non-ATPase 14 (PSMD14) affected the degradation of E2F1 and regulated the stability of E2F1. Interestingly, ECT2 regulated the expression of PSMD14.
CONCLUSION: In this study, we clarify a new mechanism by which ECT2 regulates the expression of PTTG1 and thus affects the proliferation of glioma cells: ECT2 influences the stability of E2F1 by regulating the expression of the deubiquitinating enzyme PSMD14, thereby affecting the expression of PTTG1. Intensive and extensive understanding of the mechanism of ECT2 in glioma proliferation may provide an opportunity for the development of new molecular therapeutic targets for glioma treatment.
© The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ECT2; PSMD14; PTTG1; proliferation; ubiquitination

Mesh:

Substances:

Year:  2019        PMID: 30590814      PMCID: PMC6422441          DOI: 10.1093/neuonc/noy207

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  30 in total

Review 1.  Ubiquitin networks in cancer.

Authors:  Vladimir Kirkin; Ivan Dikic
Journal:  Curr Opin Genet Dev       Date:  2010-11-09       Impact factor: 5.578

2.  Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma.

Authors:  Bill Wondergem; Zhongfa Zhang; Dachuan Huang; Choon Kiat Ong; Julie Koeman; David Van't Hof; David Petillo; Aikseng Ooi; John Anema; Brian Lane; Richard J Kahnoski; Kyle A Furge; Bin Tean Teh
Journal:  Cancer Res       Date:  2012-07-17       Impact factor: 12.701

3.  Bex2 controls proliferation of human glioblastoma cells through NF-κB signaling pathway.

Authors:  Qingming Meng; Tongle Zhi; Yuewen Chao; Er Nie; Xuebin Xu; Qiong Shi; Lei Hua; Lei Wang; Wenjian Zhan; Yong Wang; Xiuping Zhou; Rutong Yu
Journal:  J Mol Neurosci       Date:  2014-01-04       Impact factor: 3.444

4.  RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene.

Authors:  T Eguchi; T Takaki; H Itadani; H Kotani
Journal:  Oncogene       Date:  2006-07-24       Impact factor: 9.867

5.  MicroRNA-520d-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting PTTG1.

Authors:  Tongle Zhi; Kuan Jiang; Xiupeng Xu; Tianfu Yu; Weining Wu; Er Nie; Xu Zhou; Xin Jin; Junxia Zhang; Yingyi Wang; Ning Liu
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

6.  Constitutively active RhoA inhibits proliferation by retarding G(1) to S phase cell cycle progression and impairing cytokinesis.

Authors:  Pierre Morin; Cristina Flors; Michael F Olson
Journal:  Eur J Cell Biol       Date:  2009-06-09       Impact factor: 4.492

7.  The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer.

Authors:  Edgard Graner; Dan Tang; Sabrina Rossi; Antonella Baron; Toshiro Migita; Lisa J Weinstein; Mirna Lechpammer; Dieter Huesken; Johann Zimmermann; Sabina Signoretti; Massimo Loda
Journal:  Cancer Cell       Date:  2004-03       Impact factor: 31.743

8.  A proteomics approach to understanding protein ubiquitination.

Authors:  Junmin Peng; Daniel Schwartz; Joshua E Elias; Carson C Thoreen; Dongmei Cheng; Gerald Marsischky; Jeroen Roelofs; Daniel Finley; Steven P Gygi
Journal:  Nat Biotechnol       Date:  2003-07-20       Impact factor: 54.908

9.  Matrix metalloproteinase-10 is a critical effector of protein kinase Ciota-Par6alpha-mediated lung cancer.

Authors:  L A Frederick; J A Matthews; L Jamieson; V Justilien; E A Thompson; D C Radisky; A P Fields
Journal:  Oncogene       Date:  2008-04-21       Impact factor: 9.867

Review 10.  Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond the Usual Suspects' review series.

Authors:  Fumiyo Ikeda; Ivan Dikic
Journal:  EMBO Rep       Date:  2008-06       Impact factor: 8.807

View more
  25 in total

1.  ECT2 promotes malignant phenotypes through the activation of the AKT/mTOR pathway and cisplatin resistance in cervical cancer.

Authors:  Xiaoli Liu; Junhua Zhang; Shuang Ju; Lu Liu; Yu Sun; Lingyu Guo; Qianwei Zhen; Sai Han; Wei Lu; Youzhong Zhang
Journal:  Cancer Gene Ther       Date:  2022-09-02       Impact factor: 5.854

2.  A positive feedback loop of CENPU/E2F6/E2F1 facilitates proliferation and metastasis via ubiquitination of E2F6 in hepatocellular carcinoma.

Authors:  Yingyi Liu; Ye Yao; Bo Liao; Hao Zhang; Zhangshuo Yang; Peng Xia; Xiang Jiang; Weijie Ma; Xiaoling Wu; Chengjie Mei; Ganggang Wang; Meng Gao; Kequan Xu; Xiangdong GongYe; Zhixiang Cheng; Ping Jiang; Xi Chen; Yufeng Yuan
Journal:  Int J Biol Sci       Date:  2022-06-21       Impact factor: 10.750

3.  Integrated Analysis of ECT2 and COL17A1 as Potential Biomarkers for Pancreatic Cancer.

Authors:  Wen-Liang Huang; Shu-Fen Wu; Xiao Huang; Shan Zhou
Journal:  Dis Markers       Date:  2022-06-08       Impact factor: 3.464

4.  Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.

Authors:  Hui Shi; Shuo Sun; Haoyue Xu; Zongren Zhao; Zhengzhong Han; Jun Jia; Dongmei Wu; Jun Lu; Hongmei Liu; Rutong Yu
Journal:  Int J Nanomedicine       Date:  2020-05-12

Review 5.  [Advancement of E2F1 in Common Tumors].

Authors:  Cheng Shen; Jue Li; Shuai Chang; Guowei Che
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-10-20

6.  Double-targeting CDCA8 and E2F1 inhibits the growth and migration of malignant glioma.

Authors:  Xiaoxiong Wang; Heping Wang; Jiajun Xu; Xu Hou; Haoqiang Zhan; Yunbo Zhen
Journal:  Cell Death Dis       Date:  2021-02-01       Impact factor: 8.469

7.  ECT2 Increases the stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer.

Authors:  Junxiong Wang; Shuo Yang; Li Min; Shengtao Zhu; Shuilong Guo; Shutian Zhang
Journal:  Front Oncol       Date:  2021-02-08       Impact factor: 6.244

8.  miR-1258 Attenuates Tumorigenesis Through Targeting E2F1 to Inhibit PCNA and MMP2 Transcription in Glioblastoma.

Authors:  Hongkun Qin; Yanping Gui; Rong Ma; Heng Zhang; Yabing Guo; Yuting Ye; Jia Li; Li Zhao; Yajing Wang
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

9.  Reduction of SCUBE3 by a new marine-derived asterosaponin leads to arrest of glioma cells in G1/S.

Authors:  Peng-Cheng Qiu; Yun-Yang Lu; Shan Zhang; Hua Li; Han Bao; Yu-Qiang Ji; Fei Fang; Hai-Feng Tang; Guang Cheng
Journal:  Oncogenesis       Date:  2020-08-06       Impact factor: 7.485

10.  Upregulation of deubiquitinase PSMD14 in lung adenocarcinoma (LUAD) and its prognostic significance.

Authors:  Ling Zhang; Hui Xu; Chunping Ma; Jieru Zhang; Yuanjie Zhao; Xiaomei Yang; Shusheng Wang; Dawei Li
Journal:  J Cancer       Date:  2020-03-04       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.